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Abstract
Objective. Patients receiving chemotherapy are prone to neutropoenic infections, presenting with
non-specific symptoms such as a high fever and elevated inflammatory parameters. Large-vessel vas-
culitis (LVV) may have a similar clinical presentation and should be included in differential diagnostics.
A few published case reports and adverse event reports suggest a causal association between LVV
and the use of granulocyte colony-stimulating factor (G-CSF) and chemotherapy. Our objective was to
evaluate the relationship between LVV, G-CSF and chemotherapy.
Methods. Between 2016 and 2018, we identified six patients in Finland with probable drug-induced
LVV associated with G-CSF and chemotherapy. All six patients had breast cancer. A systematic litera-
ture review was performed according to PRISMA guidelines using comprehensive search terms for
cancer, chemotherapy, G-CSF and LVV.
Results. The literature search identified 18 similar published case reports, of which most were pub-
lished after 2014. In all patients combined (n¼ 24), the time delay from the last drug administration to
the LVV symptoms was on average 5 days with G-CSF (range¼ 1–8 days) and 9 days with chemother-
apy (range¼ 1–21 days). Common symptoms were fever (88%), neck pain (50%) and chest pain (42%).
Based on imaging, 17/24 (71%) had vascular inflammation in the thoracic aorta and supra-aortic ves-
sels, but 5/24 (21%) reportedly had inflammation limited to the carotid area.
Conclusion. This review suggests that LVV may be a possible serious adverse event associated with
G-CSF and chemotherapy. Successful management of drug-induced LVV requires early identification,
through diagnostic imaging, and discontinuation of the drug.
Key words: granulocyte colony-stimulating factor, vasculitis, aortitis, chemotherapy, febrile neutropoenia, ad-
verse drug reaction, large vessel vasculitis
Key messages
. Clinicians and radiologists should be aware of the large-vessel vasculitis associated with granulocyte colony-
stimulating factor or chemotherapy.
. Symptoms of large-vessel vasculitis developed within days after the administration of the suspected drug.
. Early discontinuation of the suspected drug is essential for fast recovery.
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Introduction
Patients receiving chemotherapy have an increased risk
for severe neutropoenic infections that present with non-
specific symptoms such as high fever, general malaise
and elevated inflammatory parameters. Large-vessel
vasculitis (LVV) may have an identical clinical presenta-
tion and should be included in the differential
diagnostics.
Vasculitides include a heterogeneous group of dis-
eases characterized by inflammation of blood vessels.
LVV affects the aorta and its major branches [1], causing
inflammation of the media and adventitia that leads to
subsequent luminal narrowing and occlusion [2].
Patients with LVV have increased risk for developing
complications such as an aortic dissection or an aneu-
rysm [3]. Carotidynia is a term referring to a pain in the
carotid area. It is a poorly understood vascular inflam-
mation of the carotid artery with an unknown aetiology
[4]. A controversy exists over whether this is a distinct
disease entity or a symptom attributable to other causes
of neck pain, such as vasculitis. Imaging data often
show perivascular inflammation without clear irregularity
of the vascular lumen [5, 6]. The clinical presentation
may be identical to vasculitis.
Granulocyte colony-stimulating factor (G-CSF) is a
widely used drug to reduce neutropoenia associated
with myelosuppressive chemotherapy. Until 2018,
there were limited case reports showing that LVV
was associated with G-CSF or chemotherapy. A few
reports considered docetaxel to be the causative agent
[7, 8]. Recent reports have shown that G-CSF is associ-
ated with aortitis. In February 2018, the European
Medicines Agency stated that there may be a causal as-
sociation between aortitis and G-CSF treatment
(Pharmacovigilance Risk Assessment Commitee recom-
mendations on signals EMA/PRAC/59224/2018).
Recently, two independent drug adverse event database
studies have found cases with probable G-CSF-induced
aortitis [9] and that G-CSF treatment was associated
with a sign for an increased risk for aortitis in patients
with malignancies [10]. However, the number of reported
cases is limited, and this finding requires confirmation.
Here, we describe six new patient cases within the
past 3 years, who had a probable drug-induced LVV as-
sociated with G-CSF and chemotherapy for breast can-
cer. The symptoms developed shortly after the new
drugs were started. We explored the connection be-
tween LVV, G-CSF and chemotherapy through our case
studies and the systematic literature review.
Methods
Our case series
Six consecutive patient cases were identified between
2016 and 2018 from the Departments of Rheumatology
at Turku University Hospital and Helsinki University
Hospital, Finland. As clinicians, we paid attention to this
unusual phenomenon. All patients suffered from breast
cancer and fulfilled the inclusion criteria for the study.
Informed written consent was acquired from the
patients. All patients had a minimum of 6 months of clini-
cal follow-up and a follow-up imaging, which varied
from case to case. Detailed patient cases are described
in the supplementary material, section Patient series
from the Turku and Helsinki University Hospitals, avail-
able at Rheumatology Advances in Practice online. We
had Institutional Review Board approval for the study.
Literature search
Three authors (K.T., S.H. and L.P.) conducted two sepa-
rate systematic literature searches in MEDLINE via
PubMed to find reports about cancer patients receiving
chemotherapy or G-CSF or both, before the onset of
new LVV. The first search was performed in April 2019
by using comprehensive search terms for cancer, che-
motherapy and LVV. Our interest was breast cancer, but
other malignancies were not excluded if they showed up
in the search.
The other systematic literature search was performed
in April 2019 to assess the connection between G-CSF
and LVV by using comprehensive keywords for LVV and
G-CSF with no restrictions embedded in the search
terms.
The PRISMA guidelines were followed. Retrieved and
relevant papers were searched manually for additional
references, but no new essential articles were found.
The search terms used are provided in the supplemen-
tary material, section Search terms for systematic litera-
ture review, available at Rheumatology Advances in
Practice online.
Selection of cases
The inclusion criteria were as follows: a patient with ma-
lignancy, who had received chemotherapy or G-CSF
and was diagnosed with new LVV <12 months after initi-
ation of new chemotherapy or G-CSF. The exclusion cri-
teria were as follows: a temporal relationship between
the drug and LVV that was unclear or lasting
>12 months; a cause other than an adverse drug reac-
tion (ADR) that was the more probable aetiology for LVV
(e.g. infection, mechanical causes); unclear or scarce in-
formation to evaluate the possibility of an ADR; and/or a
vasculitis other than LVV. In this study, patients with the
diagnosis of carotidynia were included in the LVV group,
because all cases showed strong carotid artery inflam-
mation with constitutional symptoms similar to LVV.
Studied parameters
We gathered the standardized information, when avail-
able, from all patient cases. The data consisted of age
at diagnosis, sex, the administered G-CSF or chemo-
therapy, affected blood vessels, symptoms associated
with LVV, the time interval from drug administration to
symptoms, diagnostic testing methods, imaging find-
ings, diagnosis as described by the authors, treatment
used for LVV, chemotherapeutic treatment strategy and
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whether cancer was considered macroscopic at the
time of G-CSF or chemotherapy.
Results
Our case series of six patients
Six female patients from Turku and Helsinki University
Hospitals between 2016 and 2018 represent our own
cases. All patients had breast cancer, and they received
both G-CSF and docetaxel. The timeline of the drug use
and symptom development of these patients is pre-
sented in Fig. 1, which shows all the chemotherapy and
G-CSF administrations before the onset of LVV.
Patients developed LVV symptoms (such as fever,
chest and neck pain, general malaise) within 8 days af-
ter the last G-CSF treatment and 9 days after the ad-
ministration of the last dose of chemotherapy, which
was docetaxel in 5/6 and 5-fluorouracil, epirubicin and
CYC in 1/6 patients, respectively (Fig. 1). The onset and
clinical characteristics of their symptoms and the imag-
ing findings were remarkably similar (Table 1).
Upon US, there was diffuse and hypoechoic wall
thickening in affected vessels (Fig. 2). CT showed a peri-
vascular mass and diffuse thickening of the vessel walls
(Figs 2 and 3). Upon MRI, there was increased signal in-
tensity, indicating oedema around the vessels, on T2-
weighted fat saturation/short tau inversion recovery
images and perivascular contrast enhancement in the
same areas on T1-weighted images (Figs 2 and 3).
Literature review search results
The search strategy from the two literature searches
resulted in a total of 1624 records, which were screened,
and of those, 48 articles (51 case reports) were evaluated
in detail. Fourteen patients were excluded because they
did not receive either cancer treatment medicine or G-
CSF before LVV. Six patient cases were excluded owing
to the use of cancer immunotherapy treatments, which
have a known association with immunological side-effects
[11]. Four cases had no inflammation in the large vessels.
Five cases were excluded owing to insufficient informa-
tion regarding cancer treatment. Four cases were ex-
cluded for the following reasons: mechanical trauma to
the aorta; an 18 year delay between drug administration
and symptoms; the patient had LVV before treatment;
and information was limited to assess ADR. Eighteen
patients met our criteria and were included in the study
(Supplementary Fig. S1, available at Rheumatology
Advances in Practice online). Altogether, 24 cases were
included in the study when literature search results and
our case series were combined (Supplementary Table S1,
available at Rheumatology Advances in Practice online).
Clinical characteristics and vasculitis distribution in
all patients (n5 24)
The mean age was 59 years (range¼40–77 years), and 18/
24 (75%) were female. The most prevalent cancer types
were breast cancer (10/24, 42%), haematological
malignancies (7/24, 29%) and lung cancer (3/24, 13%).
The most common clinical symptoms were fever (21/24,
88%), neck pain (12/24, 50%) and chest pain (10/24,
42%). Based on imaging, 17/24 (71%) had vascular in-
flammation in their thoracic aorta and their supra-aortic
vessels and 5/24 (21%) reportedly only in their carotid
area.
Drug history in relationship to vasculitis
manifestation in all patients (n5 24)
The time delay from the last drug administration to LVV
symptoms was on average 5 days (range¼1–8 days)
with G-CSF and on average 9 days (range¼ 1–21 days)
with chemotherapy.
In 16/24 cases, data from G-CSF administration were
provided: five patients had filgrastim, four had pegfil-
grastim, three patients had lipegfilgrastim, two had an
unspecified product, one had lenograstim and one pa-
tient had been treated with both filgrastim and pegfil-
grastim. Within the past 12 months, 23/24 patients had
received chemotherapy, mostly a combination chemo-
therapy (14/23, 61%). Docetaxel was the most prevalent
single chemotherapy drug, because 11/23 (48%)
patients had used it. For anticancer monotherapy, four
had received docetaxel, one patient received gemcita-
bine and one decitabine.
The exact temporal data for G-CSF administration
were provided for 13/16 patients and the exact temporal
data for chemotherapy administration for 16/23 patients,
including all breast cancer patients. In other cases, time
data were less detailed (e.g. during the first cycle of
chemotherapy), and information was not used for
statistics.
Chemotherapy and G-CSF were reportedly given in
conjunction to 15 patients (nine literature cases and our
six cases). In seven published cases, the authors as-
sumed that G-CSF was the primary cause of LVV al-
though patients also received chemotherapy [12–17]. In
one report [7], LVV was considered to be a result of ei-
ther chemotherapy or G-CSF. One article considered
only chemotherapy to be associated with LVV, although
the patient also received G-CSF [18]. In eight cases,
there were no data about the use of G-CSF. In those
reports, chemotherapy was considered to cause an ad-
verse drug reaction in four cases [8, 19–21]. The other
four patients [22–25] had haematological malignancies,
and the possibility of ADR was not discussed; instead,
in two reports [24, 25], the authors considered LVV as a
paraneoplastic phenomenon.
Discussion
Own patient cases and similar cases from the
literature search
This detailed case series is, to our knowledge, the
largest and, together with the systematic literature re-
view, emphasizes the connection between LVV, G-CSF
and, possibly, docetaxel. Our six patients developed
Drug-induced large-vessel vasculitis
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FIG. 1 Timelines of the presented cases 1–6
Abbreviations: DG: diagnosis; DOC: docetaxel; FEC: 5-fluorouracil, epirubicin and CYC; FIL: filgrastim; LIP: lipegfil-
grastim; MTH: a month mark; PEG: pegfilgrastim; PER: pertuzumab; SYM: symptoms; TRA: trastuzumab.
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symptoms within 9 days after administration of the last
G-CSF and chemotherapy, which was docetaxel in 5/6
patients. Discontinuation or change of therapy and, in
some cases, glucocorticoid (GC) treatment resulted in
drastic improvement of symptoms. In our series, doce-
taxel was discontinued in four patients, and in two
patients the dosage was reduced to avoid the need for
G-CSF. Management decisions, including GC therapy,
were made by the clinicians. We did not find a connec-
tion with co-morbidities, such as other autoimmune dis-
eases. None of the patients had a relapse in LVV during
their follow-up examinations. When compared with the
clinical presentation of the idiopathic LVV, our cases re-
covered faster with less medication.
Four cases similar to ours were found in the literature
review [8, 13, 17]. All four patients suffered from breast
cancer and received chemotherapy with docetaxel and
trastuzumab. Patients developed symptoms within
15 days (average¼ 8 days) after the last cycle of chemo-
therapy and within 7 days after their last G-CSF treat-
ment (one author [8] did not provide information about
the G-CSF). All patients had a high fever and a CRP
>200 mg/l. Imaging studies showed perivascular inflam-
mation and wall thickening, especially around the aorta
and the supra-aortic arteries. Although clinical pictures
and findings were similar, the authors had different inter-
pretations of ARD aetiology, because Chino et al. [13]
and Parodis et al. [17] considered G-CSF to be the
FIG. 2 Different imaging techniques showing vascular inflammation in the carotid area in Patient 1
(A) US images of both common carotid arteries (CCA) showing normal right CCA and abnormal left CCA with a hypo-
echoic and thickened wall. (B) CT on the same day shows a perivascular mass around the left CCA. (C, D) Next day,
with MRI: T2-weighted Dixon image (C) shows perivascular increased signal intensity around the left CCA, and the
same areas are enhanced on a T1-weighted, fat-saturated, post-contrast image (D). (E, F) Five weeks afterwards,
with a control US, the wall of the left CCA was normal.
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causative agent, whereas Azar et al. [8] concluded that
chemotherapy was suspected to be the causative
agent.
After the recovery from LVV, several patients contin-
ued to receive trastuzumab without signs of vasculitis.
Connection between G-CSF and LVV
Two drug adverse reaction database-related studies
concerning G-CSF-induced aortitis have recently been
published [9, 10]. In October 2018, Lardieri et al. [9]
published a report of 15 patients, supporting the causal
association between aortitis and G-CSF. Thirteen
patients received concomitant chemotherapy for under-
lying cancer. However, the authors thought that aortitis
was unlikely to be attributed to drugs other than G-CSF
or malignancy. Four of those cases were previously
published [12, 16, 26, 27] and the others were previously
unreported. In February 2019, Oshima et al. [10]
reported results from a Japanese database identifying
25 cases of aortitis in patients with malignancies, of
which 16 cases had a possible association with G-CSF
[10]. The authors concluded that G-CSF was associated
with a sign for an increased risk for aortitis.
In our literature search, 10 published cases had re-
ceived G-CSF before the onset of LVV. Six authors
considered LVV possibly to be connected to G-CSF [7,
12–16]. In one study, the authors considered LVV as
a paraneoplastic phenomenon in the setting of myelo-
dysplastic syndrome [25], and in another study, the
authors associated LVV with gemcitabine therapy [18].
Paraneoplastic syndrome is very rare in breast cancers,
FIG. 3 Aortitis in Patient 2
(A, B) CT shows diffuse wall thickening in the thoracic aorta and in the arteries ascending from the aortic arch. (C,
D) Six days later, MRI shows that there is increased signal intensity around the thoracic aorta on the short tau inver-
sion recovery image (C) and contrast enhancement in the same areas on T1 weighted, post-contrast Dixon images
(D). (E) Three months afterwards, with a control CT showing that the wall of the thoracic aorta has recovered.
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and we could not find any cases where breast cancer it-
self caused vasculitis in large vessels. The paraneoplas-
tic phenomenon associated with breast cancer seems
to involve the nervous system and other non-vascular
based systems [28].
Interestingly, in both database studies of suspected
G-CSF-induced aortitis [9, 10], there was a large in-
crease in reports after 2016. The same phenomenon
was observed in our systematic literature review
(Supplementary Table S1, available at Rheumatology
Advances in Practice online), because only two cases
were published before 2010. This raises important ques-
tions about whether G-CSF- and chemotherapy-induced
LVV is a new phenomenon or the possibility that this en-
tity has remained elusive owing to a lack of awareness
and underdiagnosis. Long-acting pegylated G-CSF is
relatively new to the market. Pegfilgrastim was associ-
ated with aortitis in 9/15 cases by Lardieri et al. [9] and
in 11/16 cases by Oshima et al. [10]. However, there
were several patients who developed aortitis after treat-
ment with filgrastim and a few after lenograstim. We
also found three published cases where patients without
malignancy developed LVV after administration of G-
CSF [26, 27, 29].
Based on the information gathered from our case se-
ries and from our systematic literature search, it seems
possible that G-CSF may cause LVV as an ADR alone
or together with chemotherapy. LVV does not seem to
be specific to any G-CSF.
Connection between chemotherapy and LVV
In the literature review cases, 17/18 patients received
chemotherapy before LVV. Ramsay et al. [20] and
Bendix et al. [21] have reported a gemcitabine-
associated LVV. In those cases, gemcitabine was used
in combination with docetaxel, and there were no data
about the use of G-CSF. According to our patient cases,
docetaxel and/or G-CSF could have been the drug in-
ducing vasculitis. In addition to the two cases men-
tioned above, in four cases [7, 8, 18, 19] chemotherapy
was assumed to be at least a contributing factor in
causing the LVV, and the drugs associated with the
symptoms were docetaxel and gemcitabine.
Oshima et al. [10] recently published an observational
study of 102 014 cancer patients documented in the
JADER database, of whom 98 630 were not treated
with G-CSF, and nine of those patients developed aorti-
tis. Out of all the patients, 5234 received carboplatin,
8220 bevacizumab and 7345 paclitaxel, and in each
group there emerged eight, four and eight cases of aor-
titis, respectively. Docetaxel and paclitaxel are both tax-
anes. In our data, docetaxel was the most used
chemotherapy drug (Supplementary Table S1, available
at Rheumatology Advances in Practice online); therefore,
the possible connection of LVV to taxanes is worth con-
sidering. In our material, five patients (Supplementary
Table S1, available at Rheumatology Advances in
Practice online) were treated with carboplatin, and most
patients received carboplatin during longer periods with-
out adverse events.
Imaging findings of LVV and carotidynia
In most patients, the findings of vasculitis were in the
aorta and supra-aortic vessels. Interestingly, in our ma-
terial, 5/22 patients had symptoms and, reportedly, find-
ings only in the carotid vessels suitable for carotidynia
[30–32]. Our own six patients had very similar perivascu-
lar changes compared with each other. Also, the find-
ings were in agreement with the 18 cases found in the
literature (Supplementary Table S1, available at
Rheumatology Advances in Practice online). US imaging
shows a circular wall thickening of the affected vessel
[7, 21, 33]. Cross-sectional imaging (CT and MRI) shows
perivascular, enhancing tissue around the vessel [7, 21,
30, 33, 34]. Diagnostic imaging is crucial when making a
diagnosis of LVV and carotidynia. Imaging studies are
also needed to exclude other vascular conditions caus-
ing neck or chest pain, such as dissection, thrombosis,
atherosclerosis, fibromuscular dysplasia, migraine and
aneurysm formation. Confirmed carotidynia should im-
prove by itself, without the need for GC treatment [31].
However, differential diagnostics with vasculitis are chal-
lenging, and clinicians are forced to treat patients with
presenting symptoms. In many cases, the exact diagno-
sis remains elusive.
Pathobiological aspects
The pathobiology of LVV in association with docetaxel
might involve mechanisms related to the mode of action
of docetaxel, which could be potentiated by G-CSF.
Through its effects on microtubule reorganization [35],
docetaxel could interfere with several cellular functions,
including complement receptor-mediated endocytosis
[36] and granule exocytosis [37]. This could predispose
individuals to vasculitis by mechanisms related to the
clearance of immune complexes, the cytotoxic functions
of CD8 T cells and through macrophage activation.
An interesting consideration is the possible interfer-
ence in immune complex clearance by docetaxel [36]
and activation of neutrophils on endothelial surfaces.
Immune complexes are ligands of neutrophil phagocytic
receptors. When precipitated on surfaces such as vessel
walls in the vasa vasorum, engagement of neutrophil
receptors by these ligands could induce neutrophils to
secrete their lysosomal enzymes and free oxygen radi-
cals on the surface of endothelial cells [38]. By promot-
ing neutrophils, G-CSF could perhaps act in synergy
with docetaxel to promote vascular inflammation and
injury.
Strengths and limitations
This study has limitations. It was retrospective; hence,
all detailed data were not available for literature cases.
Some literature cases do not include detailed descrip-
tion of the extent to which the vascular territories were
evaluated apart from the diagnostic finding. Also,
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comprehensive biological markers and tissue samples
were not available. The effect of paraneoplastic syn-
drome as part of the aetiology of LVV cannot be ex-
cluded completely.
A strength of the study was the systematic literature re-
view, and our patient cases were current, with excellent
patient records and imaging studies. In our patient series,
5/6 patients had all large-vessel territories evaluated.
Future considerations
It is important to keep the possibility of drug-induced
LVV in mind when treating patients with G-CSF and che-
motherapy. LVV is a serious condition that requires
prompt diagnosis, and it may result in complications
such as arterial wall dissection. Based on currently avail-
able data, there is high suspicion of a connection be-
tween G-CSF, docetaxel and LVV. However, based on
the published data, this causality is not certain, and fur-
ther studies are needed.
Conclusions
LVV is a possible serious rare adverse event associated
with G-CSF and chemotherapy. Symptoms, such as fe-
ver and chest pain, can develop within 2 weeks after
the last drug administration. We assume that LVV is of-
ten underdiagnosed. Diagnostic imaging (i.e. US, CT
and MRI) plays a major role in making a successful di-
agnosis of LVV. Accurate management of LVV requires
early identification and discontinuation of the drug. This
potentially severe ADR should be taken into consider-
ation when treating oncological patients with G-CSF.
When diagnosed and treated properly, the patients’ re-
covery time is usually short.
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